TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Instagram Outage Disrupts Thousands of U.S. Users 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
TUCSON, Ariz., Sept. 06, 2017 -- HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of instruments, reagents and services for molecular profiling applications, today announced its management will present at the Rodman and Renshaw 19th Annual Global Investment Conference in New York City on Monday, September 11, 2017, at 5:00 p.m. Eastern Time.
A live audio webcast of the presentation can be accessed by visiting the “Investors” section of the Company’s website at: http://www.htgmolecular.com. The webcast will be available on HTG's website for 90 days following the completion of the presentation.
About HTG:
Headquartered in Tucson, Arizona, the mission of HTG Molecular Diagnostics (HTG) is to empower precision medicine at the local level. The company’s HTG EdgeSeq technology, which automates sample and targeted library preparation for next-generation sequencing, received its first US Patent in 2014. Continuous improvements led to the 2017 launch of its new direct-target sequencing chemistry for DNA analysis. Additional information is available at www.htgmolecular.com.
CONTACT: Ashley Robinson LifeSci Advisors, LLC 617-775-5956 [email protected] TJ Johnson President/CEO HTG Molecular Diagnostics 520-547-2827 x130 [email protected]
